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Antibodies have high specihcity toward therr cognate antigens- Tumor-antrgcn-specific
antjboclies ^ .. .or-,ri.1.iecl ro be attractive vehicles for targeted delivery of theraper-rtic
and diagnostic agents.
This thesis tocuses on monoclonal antibody-rnediatecl targeting of lumor cells Different
freclinical (in-vitro cel1 cultures, anrmal models) and clinlcal models are used to study
ihe targetlng characterisrics of monoclonal antibodies directed againsl the human pan-
carcinoma-associated prthelial glycoprorern-2 (EGP-2, COlT-lA or Ep-CAM) and the
human epiclennal growth lactor receptor 2 (HER2)
chapter 2 gives an overview describing bnefly the chnicopathologlcal features ol cancer,
the cell typ"es involuecl and the currently available therapeutrcs and problems/hurdles
regarding t.,rllo.,dir..ted drug deliverly'Urgeting. Subsequently mole detatled descrip-
tion is giuen of rumor cell suiface .pitop.i suiuble for targeting purposes, molecular
targets rui,t'nr-r the cells for therapeutic intervention, surtable targetrng devices' drugs of
choice tor targeting as well as tn-vilro ancl in-vivo technlques Ivhich are avaiiable to study
the vanous uppro*tl.t. Finally the current clinical expellence.with targeted anti-cancer
druss is discussecl It is conclucled that monoclonal antlbodies and denvatives have
greal potentlal in drug targeting slrateEie-s'
Zfrup'i"t 3 ciescribes tf,. .pptr.^Uil ity oithe EGP2-djrected, mouse monoclonal anlibocly
MOC-31 lor in vn o raclioimmunodetection of human small cell lung cancer tSC!!-) . i i
a nucle rat xenograft model. I l l l indium]cliethylenetriaminepe.ntaacetrc-acid labeled
MOC-31 (rrrln-D'l PA,MOC-31) shows good in l ivo immunolocalisation to xenografted
SCLC cells, whereas anligen-related uptak. rs lor'v in normal rat t issues and rn a control '
antigen-negative, human derived tumol. Non-antigen-related uptake 
jn the l iver can
tr. Uio.t.Jt-,y pretreatment r,vith irrelevant antibocly It rs concluded that radiolabeled
MOC-31 retains its rmmunoreacttvity ancl shorvs goocl in vivo immrrnolocaiization to hu-
man SCLC xenograftecl in nude ral-s, a study in patients with srnall cell lung cancer
(SCLL ) was slarleo.
ir-, .hupt". 4 rhe salety and immunotargeting ploperlles of " In labeled monoclonal an-
tibocly MOC -3I (125 ftnnq, ; mg) is evaluated in srx patients r'vith histologically proven
r40 S I I{AI'ECIES FOR SPECIFIC DRUG TARGETINC; TO TUMOR CELLS
small cell lung cancer (SCLC). To this end I 'r ln is attached to the monoclonal antibody,
using DTPA as a chelator. Scintigraphy and pharmacokinetics are performed up to three
days after injection.
No adverse reactions are found after injection of MAb MOC-31. Pharmacokinetics ob-
tained fiom plasma radioactivity shows plasma dlsappearance described most properly by
a monoexponential model wrth mean hall-l i Ie value ol l7 0 tI.4 hrs.
HPLC analysis shor,vs the sole presence of radioactive monomeric MOC-31 without er,r-
dence of immune complexes or lower molecular weight fractions. Mean 24-hr urinary
excretion of radioactivity- ls 4 3 7o of the inlected dose. Scintigraphy detects primary tu-
mor and./or metastases in five of six patients, whereas localization of radioactrvity in nor-
mal (epithelial derived) tissue appears highly rest,ricted.
These prehminary results justify further studies to reveal the possible usefulness of ra-
diolabeled MOC-31 or its derivatives in the therapeutrc and diagnostic management of
SCLC.
In order to further characterize and establish the potential use of MOC-31 and its deriva-
tives in drug targeting strategies to tumor cells several additional biodistributlon studies
rn the nude rat model and in patients r,vith SCLC are performed.
These studies are described in chapter 5. First tumor bearing Wag/Rij/rnu rats receive
12.6 t 0.9 Llg of anti-EGP-2 monoclonal antibody (N{OC-31), radiolabeled with "'In-
dium using 9N3 as a chelator. 9N3 is a macrocycle (1.4.7-tri-rzoeyclononanetriacetic
acid) rvhich should form more stable complexes compared to DTPA After in-lcctron
considerable persisting uptake of " 'In-9N3-MOC-31 is seen in different organs/tissues,
such as l iver, kidnel', spleen and tumor (GLC-28) Favorable uptake in tumor tissue
compared to normal t issue was found to be present rt all-t ime points (24-72 hr) except
for kidney at24 and 48 hr. Tumor to normal t issue ratio exceeds 1.0 lbr all assessed
lrssues.
Second, to assess the uselulness and characterize "' ln-9N3-MOC-31 in a clinical setting
r group of patients (n = 7) with small cell lung cancer (SCLC) received an intravenous
inlection of approximately 5 mg "' ln-9N3-MOC-31. In patients plasma disappear-
ance curves forrl l ln-9N3-MOC-3 I are l it best by a trvo compartment model with a
biodistributlon half-l i le (t% a) of 5.5 t0.5 hr and an elimination half-1ife (t% 0) of 59.8
t 2) ) hr Signrhcrnt uptake o[ radioactlvity is found rn hver and red bone-marrolv,
rvhereas uptake in spleen and kidney ls signifrcantly less. No clear uptake in the tumor
. ' . .  f ^ , ' - . 1  \ ' ^  r ^ - i . . i r . . n f  r n r  L i n , l  r r r r *  c , ' o nw d )  l U U l l l l .  l \ U  t ( ,  l l  l l )  u '  u r
This study shows that the 9N3-MOC-31 construct can be used safelyr Although the
results in the animal model shows good bindrng properties, it was eoncluded lrom the
clinrcal results that 9N3 modified MOC-3l does not perlorm better than DTPA-modi-
f ied MOC-31.
F r r r t  he r  d r - ve lonmen t  o [  en tL -Ee  P -2  Lons tTu (  r s  rn , ]  mo lc  n re r l i c t ab le  an ima l  mode ls
i l e  nc (ess r r )  r o  op l i r n i ze  rhc  use  o f  en r i -ECP-2  r t r ns t ruc t s  rn  t l r ug  t e rge t i ng  s t | a teg ies .
( )ne  , r l  t he  poss ih l c  im f  r ( ) vcmcn ts  [ o r  r nono { .  l . r n r l  an t i bo t l i es  i r r  t a rge t i ng  s t ra teg ies  i
to produce these antiboclies by recombinant DNA technology Thrs offers the possibil-
i t 1  t o  rn ln ipu l r t e  i l r e  s i ze .  t he  shapc  end  human izc  t hc  rons ten l  r cg ions  o {  t he  MAb
molecule and to lorver immunogenrcity and improve affinitly'aviditl', effector lunctions
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SUMMARY. C.ONCLUStONS r\ND I'UTURE PERSPhCTIVES
f lexible production method was developed for recombinant monoclonal antibodies di-
rected againsr EGP-2. Such a production rs necessary to obtain enough clintcal grade
monoclonal anribodies to be used tbl preclrnrcal and ' prool of princrple" phase I clinical
studies.
We started w-ith the procluction of [scFrMOC-31],-hFc. an example of a humanized
derivative of MOC-31 further referred to as MOC-Fc.
In chapter 6 the development and pharmaceutical aspects ol productlon, purif icatron
and characterlzirtion of this recombinant MOC-Fc is described. We have shor'vn thirt it is
possible ro procluce mili igrams of the recombinant monocloual anttbodl' MOC-Fc using
CHO-Kt cells transfected with thc vcctor pEEl4 and the genes encocling MOC-Fc using
the glutar"nin synthetase (GS) system The recombinant monoclonal iintiboc'ly n.reets the
rcgulatoly requirements for this kind of anti-cancer drugs. for all i tems determined and
can be used in proof of princlple experiments
The human pancarcinoma associated epithelial glycoprotern-2 (EGP-2. CO17-1A, Ep-
CAN,'[) is a ma1or target lbr carcinoma-directed iurnunotherapy Hou'ever, EGP-2 is also
expressed ou normal epttirelial t issue . Monse monc,clonal antiboclies directed trr this 38
kDa  t ran :mcmbrane  rn l i l l en  havc  b ten  used  i n  p r t i en t s  l o r  t l i agno t i s  and  [o r  r c l i t r r r n t
treatrnent of colon carcinoma. However the potential of ar-rti-EGP-2 MAbs has becn
found to be disappointing. Recently: the use o[ engrneered humanized MAbs was suc-
cesslul in the treatrnent of B cell lymphom:rs and breast cance r. The re {ore t}re interest ir-t
anti-EGP-2 directed humar-rized MAbs rvas renerved. Hou,ever, upou use clf such ir hr-r-
manized MAb in hr.tman, severe lancreatic toxicity was observed. To evaluate lreatment-
associated elfects on tumor and normal t issue, r, l 'e have generated EGP-2 expressing
transgenic rat and mouse tumor models with the same EGP-2 expression rts in httmans
and Ln whrch we previously analyzed the behavior of ;r mouse N4Ab directed against
EGP-2. ln chapter 7 rve use the monse r-nodel to study'the tissue distribution and lumor
targetrng of trvo humanized and one mouse MAb against EGP-2 ([scFr'-MOC3l].-hFc,
USSI4, ancl MOC31) either radiolabelecl rvith "' l  or unlabeled. but tracked dor,r'n via
immunohistochemistry. Srgnificant differences in uptiike of MAb in the EGP-2 express-
ing normai tissues are seen for the three EGP-2-directed MAbs in tire transgenic tnice as
compared ro rheir behavior in the non-transgcnie rnice and tl-ris uptake is dose depend-
c l t t .  S t r i k i ng  d i l f e r cn t t ' s  r r r  b l ood  c l camn tc .  i n  I oca l i : a t i on  i r t  p ; t nc t ' c , t t i t  l l s sue  .  k i dncy
and tumor are noticed between the two humanized lgG, antibodies sharing the same
anLigenic epitope recognizing motety \r.\'e demonstrate that this EGP-2 transgenic aninral
model provrdes valuzrble insrghts in the potential behavior of hurnanized anti-EGP-2
MAbs rn humans. lt is indicated that in tire deslgn o{'hurnanrzed NlAbs, i e especrally
in rhe rnerhod used to construct the Fc-donrain, the interactton oi the antibocll.s Fc-clo-
main with Fc-receptors lror-rld be taken in carelul consideration.
We nor only studied thc targeting properrres and biodistribution of EGP-2 directed
monoclonal antibodies but also focused on trastuzumab, a recombinant humantzed
lgGl monoclonal antibody against the human epidermal gror,vth lactor receptor 2
(HER2), used for metastatic breast cancer treatrrent. Radiolabeled trastuzutnab ma;,
have several future application-s for diagnostic use lt tnigl-rt be useful for the detection of
rltmor localizations atrd also for the selection of those patients that shouid not be treated
with trastuzumab, because they are likely to develop cardiotoxrcrty:
14l
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In chapter 8 we describe the development of clinical gradeL"lndium ("' ln) radiolabeled
trastuzumab, to evaluate tl 're (serum) stabihty and immunoreactivity o[ the tracer and to
perlorm a blodlstribution study in human rumor bearing nude mice
Tiastuzuttrirb radrolabeled w'ith rl l ln uslng DTPA as a chelator rs inlected inLravenously
rnd r t  c l i l fc lcnt  ime points g loul ' rs  o l  miec ar .c  s ; r t l iheecl  - (erer ' . r l  o fgan-s rnr l  t jssucs i l re
assesse d for radioactivit l. in a galnma coLlnter.
"'In-DTPA-trastuzumab is stable and in serum the only slgr-Lrficant source of label insta-
bil i ty ls transcomplexation to transl'errln. The jmmunoreacrivity is preserved.
Biodistribution studies in tlrrnor beai-ing miee shor.vs ubstanrial uptake of rhe labeled
antibody ir-r t l 're HER2 positir"e lumor alread,v af'ter 5 h. The difference in uprake berween
HER2-pttsit ive verslls HER2-negative tumors is even morc pronounced 3 clays alier in-
lection and can be visuali:ed by radioinrnrr-rnoscintigraphv Also l iver, spleen irnd kidney
are shou,ing (probably not antigen related) marked tracer uptake.
It is concluded that trastu,umab can be efl iciently radiolabeLed wirh "' ln with high la-
beling yields and great stabil ity. rrl ln-DTPA-rrasruzumab selecrively binds to rlre human
HER2 recepttrr bolh in-vitro and in-vivo, in nude mrce. Therefore the further evi.rluatron
ol " ' ln-DTPA-trastuzumab in hurnan-s aDDears r,varrantecl.
Conclusions and future perspectives
I t  is  concluded thatr r r ln- r i ldro label led MOC-3L is  a sui table monoclonal  ant ibody for
radioimntunrrdelection o1' EGP-2 antigen-pLrsttive r-umors. Rirdlolabeled "rhr-DTPA-
lv' lOC-31 reiains its itnmunot'eactivit l ancl specificit)l ancl has good locrl i:rrion prop-
erties, \\ ' l lh high afl iniLl ' to rerger antigcns rn vivo both in experimentai rnoclels and in
patients (chapter 3 and 4) Therefore, MOC-3 1 seems to be suitable lor application as a
targeting-devrce in patients and showed in patients with SCI-C good rumor (lesions) lo-
calization. Localizatiolt in normal t issue is restricted and no adverse events arc noticed.
ln our str:clv with "' ln-DTPA-trastuzurnab w'e showed that also trastuzumab can be
h b c l . ' . 1  r i r t h h r g h l i c l c l  . r r r d g r e . r t  s l . r b r l i l r : T h r i n i r n u r r r r r c . i t t i r i t y i s p r c s c r v c t i  a n d i n t h c
internalization assay cellular retention of the "' ln label ls shor.vn. Specific tumor target-
i ng  i s  p r t r ven  i n  a  b ioc l i s t l i bu t i on  s tudy  u : i ng  human  HLR2  rumor  bea r i ng  r r r i ce .  F rom
the prechnrcal characlerization it is therefore concluded that "t ln-DTPA-trastuzumab
can be applied rn human HER2 receptor visualization and r.nay be of diagnostic value
both 1or tulror localization and therapy evaluation as well irs. possrbly, in pledicting
caldionrr.opathy (chapter 8). ParienL stuclies are ongorng
We performed an additr.rnal brodistribr-rt ion study using lr4t)C-31 andrl, ln as label but
with anolher chelator (9N3). Thrs chelator was indicated to give more stable complexes.
Despite better targeting properties in nude rats the patlent study appears to indicate that
the targeting and biodistributron characterisrics of MoC-31 is nor good enough. Espe-
cially the r"rptake in the ln'e r. l<idney ancl b(rne marrow was l-rigl-r. Comparison u,ith the
DTPA study indicate s that a part of Liris uptake rnust be labcl and,/or chelator related, i e.
due to rcleased radionr-rclide and is not clue to antibody-specil lc or non-specific uptake
in the above mentioned uormal organs/tissues. So, these clinical resuhs do not extend
the in  v i t rO and jn y iyp ' rn imr l  ernel impnral  f rndings.  The reason for  th is  iS nOt Clear
(cnaDter  )  ) .
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